Chief Accounting Officer
Whitehawk Therapeutics, Inc. (WHWK)Equibles does not estimate personal net worth.
Get an email with a short summary when Whitehawk Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get WHWK alertsScott Giacobello is recorded as Chief Accounting Officer at Whitehawk Therapeutics, Inc. (WHWK) since November 28, 2021 and CFO at Whitehawk Therapeutics, Inc. (WHWK). The newest filing on record that lists Scott Giacobello as CFO at Whitehawk Therapeutics, Inc. (WHWK) is dated April 28, 2026. Whitehawk Therapeutics, Inc. reported in an 8-K filed March 3, 2023 that Scott Giacobello was appointed Interim CEO and President, effective March 15, 2023. The proxy statement of Whitehawk Therapeutics, Inc. reports total compensation of $2,121,941 for Scott Giacobello in fiscal 2025, including a base salary of $501,561. Disclosed compensation is on record for 5 fiscal years. Scott Giacobello has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Whitehawk Therapeutics, Inc. on September 15, 2026. Whitehawk Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Whitehawk Therapeutics, Inc. includes Brendan Delaney (CEO, COO and Board Member), David J. Lennon (CEO and Board Member), David Lennon (CEO and Board Member) and 7 others.
“Effective March 15, 2023, the Board appointed Scott Giacobello, the Company's Chief Financial Officer, to serve as the Company's Interim CEO and President and principal executive officer.”
“First of all, Frank, thanks for having us here. We're happy to be here at the Morgan Stanley Conference and to tell everybody a little bit more about Whitehawk Therapeutics.”
“We ended 2024 with $47.2 million in cash, cash equivalents and short-term investments.”
“Looking at Slide 11 and starting with FYARRO. FYARRO product sales were $6.2 million for the second quarter, in line with the prior year period and up 15% over Q1.”
“We ended the first quarter 2024 with $88.3 million in cash, cash equivalents and short-term investments.”
2021-11-28–present
Start not stated–present
Last confirmed April 28, 2026
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2021-11-28–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Whitehawk Therapeutics, Inc. (WHWK) | Chief Financial Officer | $501,561 | $2,121,941 |
| 2024 | Whitehawk Therapeutics, Inc. (WHWK) | Chief Financial Officer | $483,407 | $807,929 |
| 2023 | Whitehawk Therapeutics, Inc. (WHWK) | Chief Financial Officer | $469,328 | $1,971,183 |
| 2022 | Whitehawk Therapeutics, Inc. (WHWK) | Chief Financial Officer and Former Interim President and Chief Executive Officer | $456,870 | $1,504,666 |
| 2021 | Whitehawk Therapeutics, Inc. (WHWK) | Chief Financial Officer | $75,000 | $4,091,590 |
